Last reviewed · How we verify

Escitalopram + Celecoxib — Competitive Intelligence Brief

Escitalopram + Celecoxib (Escitalopram + Celecoxib) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: SSRI + selective COX-2 inhibitor combination. Area: Psychiatry / Pain Management.

marketed SSRI + selective COX-2 inhibitor combination Serotonin transporter (SERT) and cyclooxygenase-2 (COX-2) Psychiatry / Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Escitalopram + Celecoxib (Escitalopram + Celecoxib) — University of Pennsylvania. This combination pairs a selective serotonin reuptake inhibitor with a selective cyclooxygenase-2 inhibitor to address both mood and inflammatory symptoms.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Escitalopram + Celecoxib TARGET Escitalopram + Celecoxib University of Pennsylvania marketed SSRI + selective COX-2 inhibitor combination Serotonin transporter (SERT) and cyclooxygenase-2 (COX-2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (SSRI + selective COX-2 inhibitor combination class)

  1. University of Pennsylvania · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Escitalopram + Celecoxib — Competitive Intelligence Brief. https://druglandscape.com/ci/escitalopram-celecoxib. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: